Cargando…

Colorectal Carcinoma Affected Patients Are Significantly Poor Responders Against the Oncogenic JC Polyomavirus

BACKGROUND: Many investigations reported the association between human tumors and JCPyV, a polyomavirus with oncogenic potential. The association has been supported by studies that found JCPyV footprints in CRC and gliomas of different types. Indeed, JCPyV footprints including its nucleic acids and...

Descripción completa

Detalles Bibliográficos
Autores principales: Torreggiani, Elena, Bononi, Ilaria, Pietrobon, Silvia, Mazzoni, Elisa, Guerra, Giovanni, Feo, Carlo, Martini, Fernanda, Tognon, Mauro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185217/
https://www.ncbi.nlm.nih.gov/pubmed/34113338
http://dx.doi.org/10.3389/fimmu.2021.632129
_version_ 1783704742241763328
author Torreggiani, Elena
Bononi, Ilaria
Pietrobon, Silvia
Mazzoni, Elisa
Guerra, Giovanni
Feo, Carlo
Martini, Fernanda
Tognon, Mauro
author_facet Torreggiani, Elena
Bononi, Ilaria
Pietrobon, Silvia
Mazzoni, Elisa
Guerra, Giovanni
Feo, Carlo
Martini, Fernanda
Tognon, Mauro
author_sort Torreggiani, Elena
collection PubMed
description BACKGROUND: Many investigations reported the association between human tumors and JCPyV, a polyomavirus with oncogenic potential. The association has been supported by studies that found JCPyV footprints in CRC and gliomas of different types. Indeed, JCPyV footprints including its nucleic acids and Tag oncoprotein have been revealed in CRC tissues. METHODS: Herein, sera from colorectal carcinoma (CRC) affected patients and healthy individuals (HS), employed as control, were analysed for immunoglobulin G (IgG) antibodies against specific JCPyV viral capsid protein 1 (VP1) antigens. The investigation was carried out employing an innovative immunological assay. Indeed, an indirect enzyme-linked immunosorbent assay (ELISA) with JCPyV VP1 mimotopes was used. JCPyV VP1 mimotopes consisted of synthetic peptides mimicking VP1 epitopes. RESULTS: Sera from CRC affected patients, evaluated using indirect ELISAs with synthetic mimotopes, showed a significant lower prevalence of IgG antibodies against JCPyV VP1 mimotopes (26%) compared to HS (51%), p<0.005. These data were confirmed by another method, the hemagglutination inhibition (HAI) assay. Altogether these results, i.e. the prevalence of serum IgG antibodies against JCPyV VP1 mimotopes from patients with CRC is approximately 50% lower than in HS, are of interest. DISCUSSION: Our data suggest that patients with CRC are significantly poor responders against JCPyV VP1 antigens. It is possible that CRC patients are affected by a specific immunological deregulation. This immunological dysfunction, revelled in CRC patients, may account for their predisposition to the colorectal carcinoma onset.
format Online
Article
Text
id pubmed-8185217
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81852172021-06-09 Colorectal Carcinoma Affected Patients Are Significantly Poor Responders Against the Oncogenic JC Polyomavirus Torreggiani, Elena Bononi, Ilaria Pietrobon, Silvia Mazzoni, Elisa Guerra, Giovanni Feo, Carlo Martini, Fernanda Tognon, Mauro Front Immunol Immunology BACKGROUND: Many investigations reported the association between human tumors and JCPyV, a polyomavirus with oncogenic potential. The association has been supported by studies that found JCPyV footprints in CRC and gliomas of different types. Indeed, JCPyV footprints including its nucleic acids and Tag oncoprotein have been revealed in CRC tissues. METHODS: Herein, sera from colorectal carcinoma (CRC) affected patients and healthy individuals (HS), employed as control, were analysed for immunoglobulin G (IgG) antibodies against specific JCPyV viral capsid protein 1 (VP1) antigens. The investigation was carried out employing an innovative immunological assay. Indeed, an indirect enzyme-linked immunosorbent assay (ELISA) with JCPyV VP1 mimotopes was used. JCPyV VP1 mimotopes consisted of synthetic peptides mimicking VP1 epitopes. RESULTS: Sera from CRC affected patients, evaluated using indirect ELISAs with synthetic mimotopes, showed a significant lower prevalence of IgG antibodies against JCPyV VP1 mimotopes (26%) compared to HS (51%), p<0.005. These data were confirmed by another method, the hemagglutination inhibition (HAI) assay. Altogether these results, i.e. the prevalence of serum IgG antibodies against JCPyV VP1 mimotopes from patients with CRC is approximately 50% lower than in HS, are of interest. DISCUSSION: Our data suggest that patients with CRC are significantly poor responders against JCPyV VP1 antigens. It is possible that CRC patients are affected by a specific immunological deregulation. This immunological dysfunction, revelled in CRC patients, may account for their predisposition to the colorectal carcinoma onset. Frontiers Media S.A. 2021-05-25 /pmc/articles/PMC8185217/ /pubmed/34113338 http://dx.doi.org/10.3389/fimmu.2021.632129 Text en Copyright © 2021 Torreggiani, Bononi, Pietrobon, Mazzoni, Guerra, Feo, Martini and Tognon https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Torreggiani, Elena
Bononi, Ilaria
Pietrobon, Silvia
Mazzoni, Elisa
Guerra, Giovanni
Feo, Carlo
Martini, Fernanda
Tognon, Mauro
Colorectal Carcinoma Affected Patients Are Significantly Poor Responders Against the Oncogenic JC Polyomavirus
title Colorectal Carcinoma Affected Patients Are Significantly Poor Responders Against the Oncogenic JC Polyomavirus
title_full Colorectal Carcinoma Affected Patients Are Significantly Poor Responders Against the Oncogenic JC Polyomavirus
title_fullStr Colorectal Carcinoma Affected Patients Are Significantly Poor Responders Against the Oncogenic JC Polyomavirus
title_full_unstemmed Colorectal Carcinoma Affected Patients Are Significantly Poor Responders Against the Oncogenic JC Polyomavirus
title_short Colorectal Carcinoma Affected Patients Are Significantly Poor Responders Against the Oncogenic JC Polyomavirus
title_sort colorectal carcinoma affected patients are significantly poor responders against the oncogenic jc polyomavirus
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185217/
https://www.ncbi.nlm.nih.gov/pubmed/34113338
http://dx.doi.org/10.3389/fimmu.2021.632129
work_keys_str_mv AT torreggianielena colorectalcarcinomaaffectedpatientsaresignificantlypoorrespondersagainsttheoncogenicjcpolyomavirus
AT bononiilaria colorectalcarcinomaaffectedpatientsaresignificantlypoorrespondersagainsttheoncogenicjcpolyomavirus
AT pietrobonsilvia colorectalcarcinomaaffectedpatientsaresignificantlypoorrespondersagainsttheoncogenicjcpolyomavirus
AT mazzonielisa colorectalcarcinomaaffectedpatientsaresignificantlypoorrespondersagainsttheoncogenicjcpolyomavirus
AT guerragiovanni colorectalcarcinomaaffectedpatientsaresignificantlypoorrespondersagainsttheoncogenicjcpolyomavirus
AT feocarlo colorectalcarcinomaaffectedpatientsaresignificantlypoorrespondersagainsttheoncogenicjcpolyomavirus
AT martinifernanda colorectalcarcinomaaffectedpatientsaresignificantlypoorrespondersagainsttheoncogenicjcpolyomavirus
AT tognonmauro colorectalcarcinomaaffectedpatientsaresignificantlypoorrespondersagainsttheoncogenicjcpolyomavirus